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AbstrAct:
Treatment outcome of chronic lymphocytic leukemia (CLL) has considerably 
improved since the introduction of fludarabine (F) as part of the standard therapy. 
Nevertheless,  refractoriness  to  fludarabine  occurs  in  a  significant  number  of 
patients and is associated with an unfavorable prognosis. Important risk factors 
are 17p deletion and/or mutation of TP53. For this subgroup the CD52 antibody 
alemtuzumab (A) presents a new treatment approach and has already been 
approved. Meanwhile we have to face also refractoriness to alemtuzumab. 
Importantly, the monoclonal CD20 antibody ofatumumab has now shown efficacy 
in F and A double-refractory CLL. The next generation CD20 antibody GA-101 is 
currently compared to rituximab (R) and will possibly be its more potent successor. 
Further B-cell antigens are targeted by lumiliximab (CD23), TRU-016 (CD37) and 
blinatumomab (CD19). Apart from monoclonal antibody therapies, a great number 
of  small  molecules  are  examined  for  the  treatment  of  refractory  and  relapsed 
CLL. Most of these agents aim to overcome apoptosis resistance in CLL cells or 
influence  the  microenvironment.  Typical  targets  are  regulators  of  the  cell  cycle 
and antiapoptotic molecules like the members of the Bcl-2 family. Up to now the 
most promising agents appear to be flavopiridol and lenalidomide among others.
IntroductIon
Chronic lymphocytic leukemia (CLL) is the most 
common type of leukemia in the Western world and still 
incurable. What we consider today as gold standard for first 
line treatment of patients without relevant comorbidities – 
the anti-CD20 monoclonal antibody rituximab combined 
with fludarabine and cyclophosphamide (FCR) (Fig. 1) 
[1]  –  is  often  sufficient  to  achieve  durable  remission. 
However we face serious problems if this therapeutic 
regimen fails and patients turn out to be refractory to 
fludarabine.  In  this  review  we  present  new  strategies 
beyond conventional chemotherapies which are currently 
under development or have already entered clinical trials.
Data of the German CLL Study Group’s CLL8 trial 
showed the advantage of the immuno-chemotherapeutic 
regimen FCR compared to the former standard FC [2]. 
817 patients were included. FCR treatment resulted in a 
significantly higher complete remission rate (44 % vs. 
22  %,  p<.001),  a  significantly  longer  progression  free 
survival (PFS) (44.7% vs. 64.9% at 3 years, p<.001), and 
overall survival (OS) (82.5% vs. 87.2% at 3 years, p=.01). 
It was the first time that a 1st line therapeutic choice in 
CLL showed significantly prolonged OS in a randomized 
trial and confirmed previous data in historical comparison 
performed by MD Anderson Cancer Center investigators 
(Fig. 2) [2].
FludArAbIne reFrActorIness And 
relApse
Since  more  than  20  years  fludarabine  (F)  has 
proven to be effective in the treatment of CLL. In first 
line  monotherapy,  there  have  been  response  rates  of 
63  to  80  %  [3,4].  Nevertheless  not  all  the  patients 
respond. Genetic analyses revealed the association of 
fludarabine  refractoriness  with  alterations  of  the  short 
arm of chromosome 17: 17p-deletion with mutation of 
the remaining allele of TP53 or mutation of this tumor Oncotarget 2010; 1:  472 - 482 473 www.impactjournals.com/oncotarget
suppressor  gene  without  deletion.  6  %  of  untreated 
patients show alterations in 17p but 53 % of the patients 
who were refractory to fludarabine [5,6]. A recent analysis 
of 328 cases of the CLL4 trial of the GCLLSG identified 
the deletion of TP53 as the strongest prognostic factor 
for PFS and OS (Fig. 3). Furthermore, deletion of TP53 
predicts for non-response to purine analogue based 
therapy [7,8].
Refractory  CLL  is  defined  as  no  CR/PR  or 
progression within 6 months of the last treatment time 
point, while relapse of CLL is defined as recurrence of 
the disease when the patient has reached at least a partial 
remission for 6 months after therapy. Relapse within 2 
or 3 years or refractoriness to F-based therapy influences 
the prognosis in an unfavorable way [1].New therapeutic 
strategies beyond conventional regimens like targeted 
therapy aim to enhance response and survival rates also in 
the refractory or relapsed situation.
Figure 1: FCR as first-line treatment in CLL at M. D. Anderson Cancer Center.[1,45]. A) Overall survival after response. B) Time 





Figure 2: OS in different first line treatment strategies. [1]Historical comparison of overall survival for fludarabine (F), fludarabine 
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MOnOCLOnAL AntibODieS
Rituximab
Because of the promising results of the MD Anderson 
Cancer Center and the CLL8 trial, rituximab is today part 
of the CLL gold standard treatment FCR. The monoclonal 
IgG1-antibody is directed against the CD20 antigen on B 
lymphocytes. Although CD20 expression levels on CLL 
cells is much lower than in other B cell lymphomas it has 
shown its high efficiency in CLL treatment especially in 
combination treatments.
A phase II study of rituximab monotherapy showed 
low clinical activity and short duration of response. 
Rituximab was administered weekly at the common dose 
of  375  mg/m²  over  four  weeks  [9]. The  response  rate 
in a dose escalation study in pretreated patients (either 
fludarabine  or  alkylating  agents)  was  36  %  with  only 
partial  remissions.  Response  correlated  with  dose,  the 
maximum dose given was 2.25 g/m². The group of other 
B cell lymphomas showed response in 60 % of the cases 
[10].
The strength of rituximab is combination therapy. A 
response rate of 77 % and complete remissions in 15 % 
were achieved by combination with bendamustine in a 
randomized trial of the GCLLSG. Even high risk patients 
with 11q-deletion, trisomy 12 and unmutated IGHV status 
had benefit. 17p-deleted patients showed lower response 
rates [11].
FCR  is  the  standard  regimen  in  CLL  first  line 
treatment for patients without relevant comorbidity. 
Its suitability for relapse has been examined in a phase 
II  trial  in  2005.  177  patients  were  included.  Complete 
remissions were achieved in 25 %, partial remissions in 
32 % of the cases. Overall response was 73 %. One third 
of the patients with CR had also molecular remissions 
with negative PCR results for the IGHV rearrangement of 
the CLL clone in their bone marrow. 26 % of the patients 
discontinued therapy because of heavy myelosuppression. 
Grade 4 neutropenia was seen in 41 % of the cycles and 
occurred at least once in 66 % of the patients. 16 % of the 
patients developed sepsis, pneumonia or other infectious 
complications which required hospitalization [12].
Alemtuzumab
Alemtuzumab (Campath-1H) is a monoclonal IgG1-
antibody against CD52 on mature lymphocytes. This drug 
was approved in 2001 for the treatment of fludarabine 
refractory CLL in the USA and EU. Since 2008 it is also 
approved for first line treatment of CLL in patients who are 
expected to not respond to fludarabine which is the case in 
17p-deletion or TP53 mutation. A large multicenter trial in 
the USA and Europe of i. v. alemtuzumab administration 
showed better survival data for patients with fludarabine 
refractory CLL compared to historic cohorts. 93 patients 
were  included.  CR  rate  was  2  %,  PR  was  reached  in 
31 %. Median time to progression was 4.7 months and 
median  overall  survival  was  16  months.  Transient 
Figure 3: Overall survival (OS) of genetic subgroups in the CLL4 trial (F vs. FC) of the German CLLSG (both treatment 
arms combined). [7] OS of the group with 17p13 deletion (n=16; grey), sole TP53 mutation (without 17p13 deletion) (n=14; yellow) and the 
remaining patients (n=277; blue). Median OS was significantly shorter for patients with 17p13 deletion (19.2 months) and sole TP53 mutation 
(30.2 months) than for patients without either abnormality (not reached; P < 0.001).Oncotarget 2010; 1:  472 - 482 475 www.impactjournals.com/oncotarget
infusion reactions were the most common adverse 
events, moreover infectious complications of grade 3 and 
4 in 27 % of the patients [13]. The CLL2H trial of the 
GCLLSG showed that subcutaneous alemtuzumab is as 
effective  as  intravenous  administration  in  F-refractory 
CLL. The overall response rate was 34 % with 4 % of 
complete remissions. Importantly, side effects of infusion 
reactions were markedly reduced. Efficiency was the same 
in all genetic subgroups, notably in 17p- and 11q-deletion, 
TP53 mutation and unmutated IGHV status (Fig. 4) [14].
Patients with coexpression of CD20 and CD52 
might  benefit  from  the  combination  of  rituximab  and 
alemtuzumab.  This  regimen  has  been  examined  over 
four  weeks  in  32  patients  with  relapsed  or  refractory 
CLL. Doses were once weekly 375 mg/m² rituximab and 
twice weekly 30 mg alemtuzumab (with dose escalation 
in the first treatment cycle from 3 mg over 10 mg to 30 
mg). Overall response rate was 63 % with 2 complete 
remissions and 50 % PR. Adverse events were of grade 
2 or less [15]. Another trial evaluated this combination 
in 40 pretreated patients. 64 % of them were fludarabine-
refractory. Rituximab was administered at a dose of 375 
mg/m² on day 1, then 500 mg/m² weekly over up to 3 
cycles. Alemtuzumab was first applied continuously i. v. 
at a dose of 30 mg/day for 6 days, followed by 30 mg s. c. 
twice a week from week 2 on. Infection prophylaxis was 
trimethoprim/sulfamethoxazole and valacyclovir until up 
to 3 months beyond the completion of therapy. The overall 
response rate was 53 % with 18 % of complete remissions. 
The most adverse events were again infusion-related and 
well manageable. Infections were seen in 28 % of the 
patients; 15 % of the patients developed CMF infections 
which were only detected in blood samples without organ 
manifestation [16].
The combination of fludarabine and alemtuzumab 
is called FluCAM. In a phase II trial 36 patients were 
included. A high overall response rate was reached with 
83 % (11 CR, 19 PR), but there were remarkable adverse 
events:  fungal  pneumonia  in  two  progressive  patients 
and one case of death caused by E. coli sepsis at CMV 
reactivation [17].
Alemtuzumab  has  the  highest  “single-agent” 
activity in CLL but involves risks in the form of infectious 
complications like opportunistic infections and viral 
reactivations (CMV, HSV). Obligatory is the prophylactic 
administration of cotrimoxazole and acyclovir or similar 
besides  laboratory  monitoring  of  CMV  reactivation. 
Combination  of  alemtuzumab  with  chemotherapy 
and  alemtuzumab  maintenance  approaches  remain 
experimental and should be performed in clinical trials. 
Ofatumumab (HuMax-CD20)
Like rituximab, ofatumumab binds to CD20 on the 
surface of B lymphocytes but targets a different epitope 
and showed enhance in vitro complement dependent 
Figure 4: Lack of prognostic impact of genomic aberrations in 
chemotherapy-refractory chronic lymphocytic leukemia after 
therapy  with  alemtuzumab.[14]Genomic subgroups compared 
were 17p13 deletion (n=31; black graphs), 11q22-q23 deletion (n=20; 
red graphs) and all other subgroups (n=49; green graphs). A) Median 
values for overall survival were 18.3, 22.7 and 18.6 months, respectively 
(log-rank P = 0.661). B) Median values for time to treatment failure were 
5.8, 6.8 (95% CI, 3.5 to 10.9) and 5.4 months, respectively (log-rank P 
= 0.842).
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cytotoxicity (CDC). Opposite to rituximab ofatumumab 
is completely of human origin whereas rituximab is a 
human-murine  chimeric  molecule.  Since  October  2009 
ofatumumab received accelerated approval by the FDA 
for  the  treatment  of  F  and  A  double-refractory  CLL. 
This  decision  was  mainly  based  on  two  clinical  trials: 
a  multicenter,  sequential  dose-escalating  cohort  and 
activity-estimating  trial  and  a  single-arm,  fixed-dose, 
multicenter trial.
33  patients  were  included  in  a  phase  I/II  trial  to 
evaluate safety and efficacy of ofatumumab in patients 
with refractory or relapsing CLL. In three cohorts different 
dose escalation schemes of ofatumumab were tested over 
four cycles. The maximum tolerated dose was not reached 
and all in all ofatumumab was well tolerated. The majority 
of the adverse events were infusion-related and transient 
like pyrexia, fatigue, rash, increased sweating. Infections 
were reported by 51 % of the patients. Most of them were 
of grade 1 or 2, one was fatal (infectious interstitial lung 
disease). The cohort with the highest dose (up to 2000 mg) 
achieved a response rate of 50 %. There were no complete 
remissions seen [18].
A  phase  II  trial  (NCT00349349)  examined 
ofatumumab as single-agent in patients who were either 
fludarabine-  and  alemtuzumab-refractory  (FA-ref,  n  = 
59) or fludarabine-refractory and had bulky disease (BF-
ref, n = 79) (Fig. 5). Overall response rates (measured 
during therapy) were 58 % for the FA-ref group and 47 
% for the BF-ref group. Former rituximab treatment had 
no significant influence on efficacy. 54 % of the patients 
who were pretreated with rituximab responded versus 63 
% of the patients who were not exposed (FA-ref group). 
Furthermore,  clinical  improvement  was  achieved  for 
constitutional symptoms, lymphadenopathy, splenomegaly 
and hematological parameters. Like in the dose-escalating 
study cited above, the most common adverse events were 
infusion reactions and infectious complications. Efficacy 
was lower in CLL with 17p deletion [19]. 
Lumiliximab
Lumiliximab is a chimeric monoclonal antibody 
against  CD23.  High  expression  of  CD23,  a  receptor 
for IgE, is characteristic for CLL cells; on other cells, 
expression levels are rather low. This fact provides a CLL 
specific treatment modality.
In a phase I dose-finding trial in 46 CLL patients no 
remissions were achieved, not even partially, though some 
clinical activity could be detected. Lymphadenopathy 
was reduced in 52 % of the patients, in 91 % lymphocyte 
counts were modestly decreased. Lumiliximab was well 
tolerated [20].
Based on this knowledge a phase I/II trial was initiated 
to examine the combination of FCR with lumiliximab in 
pretreated  CLL  patients.  Inclusion  criteria  were  CD23 
positivity,  progressive  disease  according  to  NCIWG 
96. Refractoriness to FCR was exclusion criterium. The 
overall response rate was 65 %, a complete remission was 
achieved in 52 % of the patients. Compared to a historic 
cohort treated with FCR [12], the CR rate was twice as 
high (52 % vs. 25 %). The toxicity was comparable [21].
tRU-016
TRU-016  is  a  SMIP  protein  (Small  Modular 
ImmunoPharmaceutical) which targets CD37. It is a so 
called single-chain polypeptide consisting of variable 
regions (scFv) and the constant regions of human IgG1. 
CD37 is expressed on normal and transformed B cells, 
low  expression  levels  are  found  on T  cells,  NK  cells, 
monocytes  and  granulocytes.  In  in  vitro  experiments 
TRU-016 appeared to be more potent than rituximab or 
alemtuzumab.
In a phase I trial 33 patients with CLL and SLL were 
included. Applicable doses and two different application 
schemes  were  evaluated.  TRU-016  was  intravenously 
delivered either once weekly over four cycles or on day 
Figure 5: Overall survival in a phase ii trial of ofatumumab as single-agent [19]. A) Overall survival in fludarabine- and 
alemtuzumab refractory patients (FA-ref). B) Overall survival in fludarabine-refractory patients with bulky disease (BF-ref)
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1, 3 and 5 over six weeks in doses of 0.03 mg/kg up to 10 
mg/kg. The drug was well tolerated with no unexpected 
toxicity.  Grade  4  neutropenia,  herpes  zoster  and  ITP 
were seen as therapy-related SAEs. At a dose of 3 mg/
kg there was detectable biological activity. One patient 
with 17p deletion achieved a partial remission whereas 
lymphocytosis decreased about 83% in the median (13 % 
up to 98 %). There was also an improvement of cytopenia 
[22].
GA-101
GA-101 is a humanized and glycoengineered anti-
CD20  IgG1  monoclonal  type  II  antibody  which  binds 
with  high  affinity.  The  resulting  antibody-dependent 
cytotoxicity is 5- to 100-fold greater than that of rituximab. 
Also direct cytotoxicity is enhanced. CD20 binding leads 
to homotypic adhesion and following cell death induction 
is non-apoptotic, actin-dependent and lysosome mediated 
[23]. Further in vitro studies showed depletion of CLL 
cells in whole blood assays and the superior efficacy of 
GA-101 compared to rituximab [24].
In a phase I trial of GA-101 in patients with relapsed 
or refractory CD20 positive NHL doses between 50 mg 
and 2000 mg were given on days 1, 8 and 22 every 3 
weeks for 9 cycles. 21 pretreated patients were included, 
33 % with high risk cytogenetics and 70 % with unmutated 
IGHV. ORR was 62 % with 1 CRi, 7 PR and 5 SD. GA-
101 was well tolerated. Infusion related reactions were 
the most frequent side effects, followed by hematological 
toxicity and infectious complications [25].
A  phase  II  study  of  GA-101  monotherapy  in 
patients  with  relapsed  CD20  positive  indolent  Non-
Hodgkin Lymphoma compares the new CD20 antibody 
to rituximab and is currently recruiting (NCT00576758). 
A  phase  III  trial  in  combination  with  Chlorambucil  in 
patients with comorbidity is currently active (CLL11 trial 
of the GCLLSG, NCT01010061).
SMALL MOLeCULeS
Flavopiridol
Flavopiridol  is  a  cyclin-dependent  kinase  (CDK) 
inhibitor which targets a broad range of CDKs. CDKs are 
involved in the regulation of cell cycle, transcription and 
mRNA processing. In CLL cell lines and primary cells 
flavopiridol induces apoptosis via activation of caspase-3 
[26].  Expression  levels  of  Mcl-1  and  XIAP  which  are 
constitutively high expressed in CLL cells are decreased 
[27].
Results  of  early  clinical  trials  were  disappointing 
[28,29]. However, in vitro studies revealed that protein 
binding of flavopiridol is much higher with human than 
with bovine serum. Accordingly, the necessary therapeutic 
concentration of flavopiridol had been underestimated and 
a revised schedule was developed. In a phase I trial 52 
patients with relapsed, symptomatic CLL or SLL were 
treated over four weeks once weekly with a loading 
dose for 30 minutes, followed by 4 hours of continuous 
infusion.  One  cycle  took  six  weeks,  six  cycles  were 
administered. 40 % of the patients achieved a PR, median 
progression  free  survival  was  12  months.  30  patients 
suffered acute tumor lysis syndrome, one patient died of it. 
Most frequent adverse events were neutropenia, diarrhea 
and cytokine-release syndrome [30]. 121 patients were 
treated according to the protocol and received infection 
prophylaxis  against  HSV/VZV  and  pneumocystis 
jirovecii. A total of 43 infectious episodes occurred in 34 
patients. Of those 22 were associated with grade 3 or 4 
neutropenia. Infectious complications were pneumonia (4 
%), bacterial sepsis (1 %), sinusitis or bronchitis (8 %), 
viral respiratory tract infections (6 %), skin- or soft tissue 
infections (4 %), catheter associated infections (6 %) and 
infections of the urinary tract infections (2 %) [31].
In  a  phase  II  trial  64  pretreated  patients  were 
included. They were treated according to the regimen 
above with 30 mg/m² by i. v. bolus followed by 30 mg/
m² as continuous infusion for the first cycle. If there was 
no severe tumor lysis syndrome, the dose for continuous 
infusion was escalated to 50 mg/m² for the second and 
following cycles. The protocol had to be changed after 
an amendment: Cycle length was reduced to 4 weeks, 
the  number  of  treatments  per  cycle  was  reduced  to  3. 
20 mg of dexamethasone were administered to prevent 
the cytokine release syndrome, ciprofloxacin was added 
and pegfilgrastim on day 16 of each cycle. 47 % of the 
patients achieved a partial, 1.6 % a complete remission. 
The treatment’s tolerability was improved. In only 2 % of 
the cases there was a tumor lysis syndrome [32].
Lenalidomide
Lenalidomide is an immune-modulating drug, in its 
structure similar to thalidomide but with more potential 
in  CLL  and  less  side  effects.  Especially  fatigue  and 
neuropathy are reduced. Teratogenicity is expected as it is 
an analog of thalidomide. In various models, lenalidomide 
inhibits  cytokines  like  TNFalpha,  VEGF  and  IL-6, 
stimulates T- and NK-cells, induces apoptosis in tumor 
cells and inhibits mitosis.
Two phase II trials examined lenalidomide in CLL. 
A dose of 25 mg p. o. daily was administered for three 
weeks in a cycle of 28 days. ORR was 47 %. 6 out of 
23  fludarabine  refractory  patients  achieved  a  PR,  one 
patient a CR. Hematological toxicity seems to be a major 
problem: in 78 % of the cases occurred neutropenia and 
thrombocytopenia  [33].  In  the  second  trial  44  patients 
were treated continuously with 10 mg daily. Every 28 
days the dose could optionally be escalated in steps Oncotarget 2010; 1:  472 - 482 478 www.impactjournals.com/oncotarget
of 5 mg up to 25 mg daily. ORR was 32 %. 7 % of the 
patients achieved CR, 10 % PR. 31 % of the patients with 
11q- or 17p-deletion (combined) responded, 24 % of the 
patients with unmutated IGHV and 25 % with fludarabine 
refractory disease [34]. A subgroup analysis of the trial 
showed that lenalidomide is also effective in patients 
with  high-risk  CLL  (combined  11q-  or  17p-deletion). 
ORR in these patients was 38 %, 19 % achieved complete 
remissions,  median  progression-free  survival  was  12.1 
months [35], however, more recent data indicate that this 
is likely due to responses in patients with 11q deletion and 
there is limited efficacy in cases with 17p deletion. 
Typical side effects of lenalidomide treatment are 
hematological toxicity and at higher doses the tumor flare 
reaction  with  lymph  node  enlargement,  leucocytosis, 
abdominal pain, fever and rashes. Tumor lysis syndrome is 
also often seen in lenalidomide treatment. Another phase 
II trial compared the doses already used in the former both 
trials: 25 mg and 10 mg. Five of 18 patients developed a 
TLS, two cases were fatal. The protocol was changed to 
a lower starting dose of 2.5 mg and slow dose escalation 
which was carefully monitored. Patients got allopurinol 
and hydration to prevent TLS. Kidney failure requiring 
dialysis before treatment was an exclusion criterium. TLS 
has not been observed in the amended protocol [36].
Oblimersen
Oblimersen is an antisense oligonucleotide which 
is applied intravenously. It inhibits the translation of the 
Bcl-2 protein which is a potent apoptosis inhibitor. In CLL 
expression levels of Bcl-2 are high.
A phase I/II trial examined oblimersen in 40 patients 
with relapsed or refractory CLL. The maximum tolerated 
dose  was  3  mg/kg/d.  Higher  doses  caused  a  cytokine 
release syndrome with or without tumor lysis within 24 
to 48 hours. 26 patients were eligible for evaluation. 8 % 
achieved a partial remission [37].
Another phase II trial in 24 patients, of whom were 19 
pretreated, the combination of oblimersen with rituximab 
and fludarabine was tested. 68 % of the pretreated patients 
responded,  one  even  achieved  a  complete  remission. 
Side effects were well manageable. Neutropenia, nausea, 
fatigue and fever, thrombocytopenia and anemia were the 
most frequent adverse events [38].
241  patients  were  included  in  a  phase  III  trial 
which compared FC and the combination of oblimersen, 
fludarabine and cyclophosphamide. 17 % of the patients in 
the experimental study arm achieved a complete or partial 
nodular remission at least for 6 months compared to 7 % 
of the patients treated with FC (p = 0.025). The five-year 
survival was significantly prolonged in patients who had 
achieved at least PR. Patients with fludarabine sensitive 
disease had most benefit [39].
Abt-263
ABT-263  is  a  BH3-mimetic  which  is  orally 
administered. It binds to all members of the family of Bcl-
2 proteins with high affinity. In lymphoma cell lines which 
express high Bcl-2 levels ABT-263 is a potent apoptosis 
inducer. EC50 is about 1 µM [40]. Primary CLL cells are 
very sensitive to ABT-737 the precursor drug of ABT-263 
which is not orally bioavailable (EC50 = 7 nM, 4 hours 
incubation time) [41].
A current phase I/IIa trial in patients with relapsed or 
refractory CLL aims to evaluate pharmacokinetics, safety 
profile and efficacy of ABT-263. Two application schemes 
are examined: first 10 to 250 mg of ABT-263 on day 1 to 14 
(21-days cycle). This led to pronounced thrombocytopenia 
as a direct toxic effect on platelets through inhibition of 
Bcl-XL. To avoid this, patients got a loading dose of 100 
mg for one week followed by a continuous application 
up to 300 mg on all 21 days of the cycle. This reduced 
fluctuation in the number of thrombocytes as well as early 
thrombocytopenia.  Most  frequent  adverse  events  were 
diarrhea, nausea and vomiting, fatigue, thrombocytopenia 
(20 %) and neutropenia (12 %). Grade 4 thrombocytopenia 
was dose-limiting in three patients of the first group, in 
the second group it was grade 4 thrombocytopenia and 
nausea also in three patients. These results lead to the 
recommendation of a loading dose of 100 mg for one 
week, followed by a continuous dose of 250 mg/d [42].
A phase I trial about the combination of ABT-263 
with FCR or BR is currently recruiting, moreover a phase 
IIb trial of different oral dosage forms (NCT00868413, 
NCT00918450).
Obatoclax
The small molecule obatoclax inhibits the binding 
of the anti-apoptotic members of the Bcl-2 family Bcl-
2, Bcl-XL, Bcl-W and Mcl-1 to the proapoptotic proteins 
Bax and Bak. This might restore the apoptotic machinery 
of tumor cells.
The  EC50  for  primary  CLL  cells  is  1.2  ±  0.1 
µM.  Synergistic  effects  are  seen  in  combination  with 
fludarabine  and  chlorambucil  [43].  Different  doses 
between 3.5 mg/m² and 14 mg/m² during one hour of 
infusion and between 20 and 40 mg/m² during 3 hours 
of infusion were tested for efficacy and safety as well 
as pharmacokinetic and pharmacodynamics in a phase 
I trial. One cycle lasted three weeks. The patients were 
pretreated  and  either  fludarabine  refractory  or  relapsed 
after  a  fludarabine  containing  standard  treatment.  One 
patient with bulky disease achieved a partial remission. 
Remarkable  were  infusion  associated  neurological  side 
effects like somnolence, euphoria and ataxia. Hemoglobin 
levels were increased in three patients which made 
them independent of blood transfusions. Also their Oncotarget 2010; 1:  472 - 482 479 www.impactjournals.com/oncotarget
thrombocytopenia had slightly improved [44].
Histone deacetylase inhibitors (HDAC inhibitors)
The secondary structure of histones is modulated 
by  posttranslational  acetylation,  methylation  and 
phosphorylation. As a result histones dissociate from 
the  DNA-strand  and  transcription  factors  can  bind  to 
their  promoters.  Deacetylation,  demethylation  and 
dephosphorylation causes the opposite.
The most well known HDAC inhibitor is valproic 
acid which is used as anticonvulsant. In primary CLL cells 
valproic acid induces dose-dependent cytotoxicity via the 
extrinsic apoptosis pathway. In combination with TRAIL 
those cells are sensitized for apoptosis. Doses between 0.5 
and 5 mM were used [45]. Clinical trials with valproic 
acid as single-agent (NCT01016990) and in combination 
with fludarabine (NCT00524667) are recruiting.
Two phase I trials on HDAC inhibitors in CLL have 
already been published. 10 patients were treated with 13 
mg/m² depsipeptide (FK228) in a dose finding study. All 
the patients were pretreated either with purine analogs 
or had a contraindication against those drugs. The cycles 
lasted four weeks, depsipeptide was applied intravenously 
on  day  1,  8  and  15.  Treatment  was  continued  for  at 
least two months up to one year. Adverse events were 
fatigue, nausea and loss of appetite. One patient suffered 
a tumor lysis syndrome with renal failure and needed 
hospitalization. There were neither partial nor complete 
remissions.  However  biological  activity  was  detected: 
histone  acetylation  was  increased  up  to  100  %,  p21 
expression was augmented [46].
Another phase I trial examined dosage and safety 
of  Belinostat  (PXD101).  18  patients  with  different 
hematological malignancies were included, two of them 
had fludarabine refractory CLL. Both were treated for two 
cycles. One cycle lasted three weeks. At a dose of 600 mg/
m² and 900 mg/m² on day 1 to 5 of each cycle they had 
stable disease. The most frequent side effects were again 
nausea and vomiting, fatigue and a flush syndrome. Doses 
up to 1000 mg/m² seem to be well tolerable. There were 
no distinct responses [47].
Gossypol/At-101
AT-101 is an enantiomer of gossypol which binds 
with high affinity to the BH3 domain of the antiapoptotic 
members of the Bcl-2 family. At a dose of 20 µM for 24 
hours AT-101 induces 72 % apoptosis in the median in 
primary CLL cells. This was also seen in coculture with 
a bone marrow stromal cell line [48]. A phase II trial in 
relapsed or refractory B cell neoplasms (NCT00275431) 
and  a  phase  II  trial  in  combination  with  rituximab 
(NCT00286780) has already been finished. Another phase 
I/II study about the combination with lenalidomide is still 
recruiting (NCT01003769).
Dasatinib
The tyrosine kinase inhibitor dasatinib has shown 
efficacy  in  CML  and  bcr/abl-positive  ALL.  Dasatinib 
inhibits  c-kit,  EGFR  and  kinases  of  the  Src-family 
(SFKs). The SFK Lyn is highly expressed in CLL cells 
and inhibition of SFK activity leads to apoptosis induction 
in primary CLL cells. Further in vitro experiments showed 
also synergistic effects of dasatinib with chlorambucil and 
fludarabine [49]. CLL cells with unmutated IGHV seem to 
respond better than those with mutation [50].
In  a  phase  II  trial  in  15  patients  a  daily  dose  of 
140 mg was administered. All patients had fludarabine 
pre-treatment, five were refractory. In 2 patients partial 
remissions were achieved, another 2 had nodal complete 
remissions,  4  had  nodal  partial  remissions.  Adverse 
events  were  mainly  neutropenia  (grade  3  and  4)  and 
thrombocytopenia (grade 3 and 4). All in all dasatinib 
showed modest activity in CLL [51].
conclusIon
Current biologically-targeted therapeutic strategies 
against relapsed and refractory CLL include antibody-
based therapies as well as small molecules. Rituximab 
in combination with chemotherapy is very effective in 
CLL and standard in first-line and second-line therapy. 
Fludarabine-refractory  patients  achieve  an  overall 
response of 33 % by single-agent alemtuzumab. Today 
we see patients who are not only fludarabine- but also 
alemtuzumab-refractory.  For  those  cases  ofatumumab 
is a promising option which has been approved for this 
situation.  Third-generation  antibodies  like  GA-101 
show in vitro even more efficacy than rituximab and are 
currently further evaluated in clinical trials. The most 
advanced small molecules are today lenalidomide and 
flavopiridol. Response rates of 20 to 45 % were achieved 
in  relapsed/refractory  CLL.  A  broad  range  of  agents 
with different mechanisms of action are in development 
or have already entered clinical trials, but the prognosis 
of chemotherapy-refractory patients is still unfavorable. 
Thus new therapeutic strategies are needed and have to 
prove not only efficacy but also a good safety profile.
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